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Background
Tramadol is a mixed centrally acting opioid analgesic
used to relieve moderate to severe pain. It is commonly
used alone or in combination with nonopioid analgesics,
for example, paracetamol (acetaminophen) in the treat-
ment for postoperative, dental, cancer, neuropathic, and
acute musculoskeletal pain [1–3]. It can also be used as
an adjuvant to NSAID therapy in osteoarthritis patients
[4]. Tramadol exerts its analgesic effect through at least
two complementary and synergistic mechanisms: by
activating the µ-opioid receptor and inhibiting the neu-
rotransmitter reuptake. The opioid receptor-mediated
analgesic effects are mainly attributed to the active
metabolite M1 (O-desmethyltramadol), whereas the
inhibition of the neurotransmitter reuptake is caused by
the parent drug, thus enhancing the inhibitory effects on
pain transmission in the spinal cord [1,5,6]. Therefore,
both the parent drug and especially the M1 metabolite
contribute toward the overall analgesic activity of
tramadol.
Tramadol is administered as a racemic mixture of
(+ )-tramadol and (− )-tramadol enantiomers (also known
as R, R and S, S tramadol, respectively). Tramadol is a
synthetic opioid belonging to the class of weak opioid
receptor agonists [step 2 analgesics according to the
WHO ladder (http://www.who.int/cancer/palliative/painlad
der/en/)]. In comparison with typical opioid agonists such
as morphine at equivalent doses, tramadol shows similar
overall analgesic efficacy, and yet appears to have a lower
potential for respiratory depression or physical depen-
dence as well as a lower incidence of constipation
[1,3,7–9]. However, cases of physical dependence and
withdrawal syndrome have been reported, especially
with long-term use of high tramadol doses [10–12]. The
dose requirements for tramadol are variable and interac-
tions with other drugs are common. Depending on the
duration of treatment and settings, there might be certain
variance in the equipotent use of tramadol and morphine.
Tramadol has been shown to be approximately equipo-
tent to morphine in the range of 4 : 1 to 5 : 1 ratio orally
(tramadol : morphine) and 10 : 1 to 12 : 1 ratio parenterally
[13–16]. Some patients experience inadequate pain relief
or adverse effects with tramadol. The main reported
adverse drug reactions (ADRs) for tramadol are nausea,
vomiting, sweating, itching, constipation, headache, and
central nervous system stimulation. Most of these reac-
tions are dose dependent. Neurotoxicity to tramadol may
manifest as seizures, which have been reported in
patients receiving tramadol both at the recommended
and the high dosage ranges in animal and human stu-
dies [17].
Tramadol metabolism to its major active metabolite M1
is predominantly mediated through CYP2D6 [18–20];
thus, CYP2D6 plays a significant role in tramadol phar-
macokinetics and variability in drug responses [21,22].
The influence of the CYP2D6 genotype on plasma levels
of tramadol and its metabolites as well as tramadol effi-
cacy and ADR have been reported [18,21,23–25] (see the
Pharmacogenomics section). This review briefly sum-
marizes the metabolism and transport of tramadol (Fig. 1)
and discusses genetic variations affecting the pharmaco-
kinetics, efficacy, and toxicity of tramadol. Knowledge of
genetic variants mediating the diverse pharmacological
profile of tramadol may help optimize opioid therapy to
achieve better control of pain and less adverse effects for
the patients.
Pharmacodynamics
Tramadol consists of two enantiomers [(+ )-tramadol and
(− )-tramadol], both of which, along with metabolite M1,
contribute toward overall analgesic activity by distinct
but complementary mechanisms [1,6]. In-vitro and clin-
ical studies showed that the parent drug is only a weak µ-
opioid receptor agonist, whereas the metabolite M1 is
significantly more potent than tramadol µ-opioid receptor
binding and in producing analgesia [22,26,27]. (+ )-M1
has a significantly higher affinity for the µ-opioid receptor
(encoded by gene OPRM1) (Ki= 0.0034 µmol/l) than the
parent drug (+ /− )-tramadol (Ki= 2.4 µmol/l) as well as
(+ /− )-M5 (Ki= 0.1 µmol/l) and (− )-M1 (Ki= 0.24 µmol/l)
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[26], suggesting that it is the compound primarily
responsible for opioid receptor-mediated analgesia. The
(+ /− )-tramadol also contribute toward analgesia by
inhibiting reuptake of the neurotransmitters serotonin
[by binding to transporter hSERT (encoded by gene
SLC6A4)] and norepinephrine [by binding to transporter
hNET (encoded by gene SLC6A2)]. The racemic tra-
madol binds to hNET and hSERT with Ki values at 14.6
Fig. 1
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and 1.19 µmol/l, respectively (reviewed by Raffa et al.
[28]). Studies with the enantiomers showed that
(− )-tramadol is more potent in inhibiting norepinephrine
uptake (Ki= 1.08 µmol/l) and stimulating α-adrenergic
receptors. In contrast, the (+ )-tramadol is more potent
than (− )-tramadol for inhibiting serotonin uptake
(Ki= 0.87 µmol/l) and enhancing serotonin release
[28,29]. Both enantiomers act synergistically to enhance
tramadol efficacy. These properties of tramadol may also
contribute toward an increased risk of serotonin toxicity
with concomitant use of serotoninergic drugs such as
serotonin reuptake inhibitors (SSRIs) (e.g. fluoxetine,
paroxetine, sertraline). SSRIs can not only inhibit tra-
madol metabolism by inhibiting CYP2D6 but also
increase serotonin levels in the central nervous system,
an effect also mediated by tramadol. Therefore, con-
comitant use of an SSRI and tramadol can lead to ser-
otonin syndrome, and should be avoided [1,13,14,30].
The FDA-approved tramadol drug label now states: ‘In
vitro drug interaction studies in human liver microsomes
indicates that inhibitors of CYP2D6 such as fluoxetine
and its metabolite norfluoxetine, amitriptyline, and qui-
nidine inhibit the metabolism of tramadol to various
degrees. The full pharmacological impact of these
alterations in terms of either efficacy or safety is
unknown. Concomitant use of SEROTONIN re-uptake
INHIBITORS and MAO INHIBITORS may enhance
the risk of adverse events, including seizures (see
WARNINGS) and serotonin syndrome’ (from
TRAMADOL HCL – tramadol hydrochloride tablet
Package Insert, http://dailymed.nlm.nih.gov/dailymed/
lookup.cfm?setid= ae7c54b1-b440-4cca-97e8-e5b825413d32).
Pharmacokinetics
Metabolism
After oral administration, tramadol is rapidly and almost
completely absorbed [6]. The mean bioavailability of
tramadol after a single oral dose is around 68% and
increased to above 90% after multiple doses [3,31]. In
healthy adult volunteers administered a 100 mg oral sin-
gle dose of tramadol, the maximum plasma concentration
(Cmax) was 308 µg/l and was reached in 1.6 h (tmax). The
renal clearance was at 6.6 l/h [3]. Tramadol is extensively
metabolized in the liver by O- and N-desmethylation and
by conjugation reactions to form glucuronides and sulfate
metabolites. The O-desmethylation of tramadol to its
main active metabolite, O-desmethyltramadol (M1), is
catalyzed by cytochrome P450 (CYP) 2D6 [19,20,32]
(Fig. 1). Enantioselective analysis of tramadol and M1
showed (–)-M1 levels being generally higher than (+ )-M1
levels [33,34]. The N-desmethylation to N-desmethyl-
tramadol (M2, not pharmacologically active) is catalyzed
by CYP2B6 and CYP3A4 [19]. M1 and M2 may then be
further degraded to secondary metabolites,N,N-didesmethyl-
tramadol (M3) and N,O-didesmethyltramadol (M5), and
then to N,N,O-tridesmethyltramadol (M4) [19]. Among all
its metabolites, only O-desmethyltramadol (M1) and to a
lesser extent N,O-didesmethyltramadol (M5), are phar-
macologically active. Following bioactivation in the liver,
M1 is released into the blood, enters the central nervous
system, and activates µ-opioid receptors. In the phase II
metabolism, M1 is inactivated by glucuronidation in the
liver, mostly through UGT2B7 and UGT1A8 [35]. The
major route of excretion for tramadol and its metabolites is
through the kidneys, with about 30% of the dose excreted
in the urine as the parent drug and the rest excreted as
metabolites. Capillary electrophoresis assay showed that
in healthy volunteers administered 150mg oral tramadol,
about 11.4% of the dose was excreted as (− )-tramadol,
16.4% as (+ )-tramadol, and 23.7% as O-desmethyl-
tramadol glucuronide in the urine [36]. This study also
observed a four-fold higher excretion of (− )-O-desmethyl-
tramadol glucuronide than the (+ )-O-desmethyltramadol
glucuronide.
As tramadol metabolism is primarily mediated through
CYP2D6, CYP3A4, and CYP2B6, drugs that inhibit
CYP2D6 or induce or inhibit CYP3A4 and CYP2B6
function should be used with caution in patients taking
tramadol because of a potential risk of drug interaction
[37,38]. For example, carbamazepine, a potent inducer of
CYP3A4, may increase tramadol metabolism through
CYP3A4 to inactive metabolites and therefore reduce its
analgesic effect [39] (TRAMADOL HCL tablet Package
Insert, http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=
ae7c54b1-b440-4cca-97e8-e5b825413d32). Paroxetine, a potent
CYP2D6 inhibitor, has been shown to significantly inhi-
bit the metabolism of tramadol to its active metabolite
M1 and reduces, but does not abolish the analgesic effect
of tramadol [40]. Escitalopram, a weak inhibitor of
CYP2D6, inhibited O-desmethylation of (+ )-tramadol,
but did not reduce the hypoalgesic effect in experimental
pain [41].
Transport
Drug transporters play important roles in drug absorption,
distribution, and excretion and may affect the analgesic
and tolerability profile of tramadol. The bidirectional
transport of racemic tramadol and its metabolites have
been investigated in a few in-vitro and clinical studies
[5,42,43]. Tramadol and its metabolites are not substrates
of the P-glycoprotein (P-gp) (ABCB1) in vitro [5]. More
recently, Tzvetkov et al. [43] reported that the hepatic
reuptake of M1, but not of tramadol, is mediated by
SLC22A1 (OCT1). The claim is supported both by
in-vitro and by clinical data. SLC22A1 (OCT1) is a
polyspecific organic cation transporter that is strongly
expressed in the sinusoidal membranes of the human
liver. The data of Tzvetkov and colleagues suggest that
after M1 is produced and excreted from the liver, it may
be taken back up by OCT1 (Fig. 1). Therefore, OCT1
may affect the plasma concentrations of M1 and thus
affect its opioidergic efficacy. The authors also found that
tramadol is an inhibitor of OCT1. However, the
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inhibition potency was rather low and clinically relevant
drug–drug interactions on the basis of inhibition of
OCT1 by tramadol are not very probable.
Pharmacogenomics
There is considerable variability in the pharmacokinetic
and pharmacodynamic of tramadol depending on the
genetic background [2,44]. This has been partly ascribed
to the CYP2D6 polymorphisms as CYP2D6 plays a critical
role in generating the M1 metabolite that contributes to
the major opioid analgesic effect. Genetic variations of
CYP2D6 have been shown to affect not only the phar-
macokinetics of tramadol and M1 but also the analgesic
efficacy in volunteer and patient studies as well as
pharmacodynamic responses [18,21,23–25,45]. In addi-
tion to CYP2D6, a few other studies have explored the
role of drug transporters and pharmacological targets in
tramadol efficacy or toxicity [42,43,46].
Metabolizing enzyme variants
Tramadol is metabolized primarily by CYP2D6, a phase I
metabolizing enzyme responsible for the activation or
clearance of about 25% of all marked drugs. CYP2D6 is
highly polymorphic, with more than 100 alleles defined
by the Cytochrome P450 Nomenclature Committee
(http://www.cypalleles.ki.se/cyp2d6.htm). CYP2D6 activity
varies considerably within a population, which leads to
distinct phenotypes. The CYP2D6 phenotype can be
classified according to the metabolizer status into ultra-
rapid metabolizers (UMs), extensive metabolizers (EMs),
intermediate metabolizers (IMs), and poor metabolizers
(PMs). The EMs carry two active, the IMs one inactive
and one reduced activity, and the PMs two inactive
CYP2D6 alleles. The UMs carry at least three active
CYP2D6 alleles because of gene duplication/multi-
plication [47–49]. The following CYP2D6 alleles are
considered active: *1, *2, *27, *33, *35, *45,*46, *39,
*48, *53. The alleles *3, *4, *5, *6, *7, *8, *11,*12, *13,
*14, *15, *16, *18, *19, *20, *21, *31, *36, *38, *40, *42,
*44, *47, *51, *56,*57, *62 are considered inactive or
nonfunctional. The alleles *9, *10, *17, *29, *41, *49,
*50, *54, *55, *59, *69, *72 are considered to have
reduced function or decreased activity [50]. CYP2D6
plays a pivotal role in the pharmacokinetics and analgesic
efficacy of tramadol. Several reduced or none functional
CYP2D6 alleles as well as alleles with multiple gene
copies have significant impacts on clinical outcome in
patients under tramadol medication [22,24,27,33,45,51–55].
Pharmacokinetic studies have shown that the impact of
CYP2D6 phenotypes on tramadol pharmacokinetics was
similar after single oral, multiple oral, or intravenous
administrations [33,52,55]. CYP2D6 PMs had increased
exposure to tramadol, but markedly reduced M1 formation
when compared with individuals with normal CYP2D6
activity (EMs) [22,27,33,52–55]. PMs tend to experience
significantly reduced analgesic effects: in a prospective study
enrolling 300 postoperative patients, the percentage of
nonresponders was significantly higher in the PM group
(46.7%) compared with the EM group (21.6%; P=0.005)
[25]. Tramadol loading doses were also higher in PMs and
more patients required rescue medication for pain relief after
surgery. In another study including 174 patients receiving
intravenous tramadol for postoperative analgesia, compar-
able findings were reported [33]: the nonresponse rates to
tramadol treatment increased four-fold compared with the
other genotypes (P<0.001) and the concentration of the
(+ )-M1 metabolite was markedly reduced in PM versus
EM or UM patients. In healthy Chinese individuals, the
reduced function allele CYP2D6*10 (a very common allele
in Asians with allele frequency of 52.4%) was associated with
altered pharmacokinetics of tramadol, but CYP2D6*2 had no
effect [56]. Chinese volunteers carrying the CYP2D6*10/*10
allele had significantly reduced tramadol clearance as com-
pared with patients carrying the CYP2D6*1/*1,
CYP2D6*2/*2 alleles, and CYP2D6*2/*10 (P<0.01).
Another study with Chinese gastric cancer patients reco-
vering from gastrectomy showed that patients with a
homozygous CYP2D6*10 allele had significantly higher tra-
madol total consumption than patients without the
CYP2D6*10 or heterozygous for CYP2D6*10 [57]. In con-
trast to PM patients who have reduced CYP2D6 function
and decreased tramadol efficacy, individuals who are
CYP2D6 UMs tend to have increased sensitivity to tramadol
and also an increased risk for adverse events. Maximum
plasma concentrations of the active metabolite M1 were
significantly higher in the UM group compared with the EM
group in a pharmacokinetic study in healthy male volunteers
[24]. Pain thresholds and pain tolerance were increased and
a more pronounced meiosis was reported in UMs under
tramadol medication as compared with EMs. However,
UMs also seem to be specifically prone to opioid/tramadol-
related side effects when compared with those with normal
CYP2D6 activity, probably because of the overall higher
(+ )-M1 concentrations. Almost 50% of the UM group
experienced nausea compared with only 9% of the EM
group [24]. Severe life-threatening adverse events were
reported in two case reports. One patient with renal
impairment carrying the CYP2D6 gene duplication experi-
enced respiratory depression [45] and another UM devel-
oped a near-fatal cardiotoxicity, in both cases because of
tramadol use [51].
On the basis of the data described above, the US FDA-
approved drug label now contains information on meta-
bolism of tramadol by CYP2D6: ‘CYP2D6 poor meta-
bolizers may have higher tramadol concentrations, and
concomitant use of CYP2D6 or CYP3A4 inhibitors such
as fluoxetine, paroxetine and quinidine could result in
significant drug interactions’. The Royal Dutch
Pharmacists Association – Pharmacogenetics Working
Group (DPWG) has also evaluated therapeutic dose
recommendations for tramadol on the basis of CYP2D6
genotypes [58]. For CYP2D6 PM and IM genotypes, they
recommend selecting an alternative drug (not oxycodone
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or codeine) and/or being extra alert to symptoms of
insufficient pain relief. For UM genotypes, they recom-
mend using a 30% decreased dose and being alert to an
increased risk of ADRs (e.g. nausea, vomiting, constipa-
tion, respiratory depression, confusion, urinary retention)
or select an alternative drug [e.g. paracetamol (acet-
aminophen), NSAID, morphine, but not oxycodone or
codeine, which also require CYP2D6 for metabo-
lism] [58].
Transporter variants
P-gp (encoded by the ABCB1 gene) is an important drug
efflux transporter in the intestine, kidney, liver, and at the
blood–brain barrier. P-gp affects the bioavailability,
eliminations, and penetration in the brain of many drugs
including some opioids. In a study with healthy volun-
teers, a functional variant in ABCB1, rs1045642
(3435C>T), has been associated with tramadol pharma-
cokinetics [42]. Individuals carrying the 3455TT geno-
type had increased Cmax values of tramadol, but this
variant neither affected the tramadol metabolic ratio nor
the parent compound’s clearance. However, a later
in-vitro study using Caco-2 cells showed that ABCB1 did
not transport tramadol or its metabolites [5]. A more
recent study showed that the hepatic reuptake of the
active metabolite M1, but not the parent drug tramadol, is
mediated by SLC22A1 (OCT1) [43]. SLC22A1 is highly
polymorphic. A number of SLC22A1 polymorphisms have
been associated with reduced protein activity as well as
with an impact on drug disposition, response, and toxicity
[59,60]. Because of the presence of five common loss-of-
function polymorphisms, about 9% of Whites lack an
active OCT1 allele and a further 41% have only one active
allele [60,61]. Tzvetkov and colleagues showed that
individuals carrying none or only one active OCT1 allele
had significantly higher plasma concentrations of M1
metabolite and longer lasting meiosis, suggesting stronger
opioidergic effects. In-vitro investigations also supported
this association showing that OCT1 overexpression
increased M1 uptake 2.4-fold. This increase in uptake
could be reversed by OCT1 inhibitors and was absent
when the common loss-of-function OCT1 variants were
overexpressed [43]. It should be noted that these loss-of-
function polymorphisms are much rarer in Africans and
are almost missing in Asians [60].
Pharmacodynamic gene variants
Tramadol is a synthetic opioid that acts at the µ-opioid
receptor (encoded by gene OPRM1) [6,62]. Opioid
receptors belong to the group of G protein-coupled
receptors. They bind to endogenous opioids (e.g.
dynorphins, enkephalins, endorphins, endomorphins,
and nociceptin) as well as to opioid drugs. They are
expressed widely in the brain, spinal cord, and digestive
tracts. By targeting the µ-opioid receptor, tramadol exerts
its analgesic as well as its addictive properties. One of the
most widely studied variant in OPRM1 is the A118G base
exchange (rs1799971) in exon 1 [63]. The A to G sub-
stitution confers an asparagine to aspartate exchange and
results in reduced OPRM1mRNA and protein levels [63].
This variant is considerably more common in Asians than
in Whites, with a minor allele frequency of 24–45% in
Asians and around 10–17% in Whites [64,65]. This var-
iant has been linked to response to many opioids,
including morphine, fentanyl, alfentanil as well as tra-
madol (reviewed by Stamer and colleagues [64,66]).
However, the results have been controversial, with both
positive and negative associations reported for this SNP
on various opioid phenotypes, for example, dose
requirement, analgesic efficacy, and side effects [65]. In a
study of 160 Korean patients treated with tramadol, the
A118G variant has been associated with ADRs [46].
Korean patients carrying the GG genotype were less
likely to develop nausea/vomiting (6.3-fold lower odds)
when treated with tramadol as compared with patients
with the AA genotype, suggesting that a high risk of
nausea/vomiting may be linked to high levels of μ-opioid
receptor expression. However, this effect has not been
replicated and a recent meta-analysis including 14 studies
and 3446 patients on opioid therapies showed very small
clinical effects for the A118G variant [65]. Although the
metastudy involves many opioids (not tramadol specific),
the overall results suggest that the clinical relevance of
the OPRM1 A118G variant as a solitary genetic marker is
limited, but this variant may be considered a part of the
complex genotypes along with other genetic and non-
genetic factors underlying pain and analgesia [65,67].
Summary
The genetic factors underlying the variation in tramadol
response are complex, and likely involve multiple genes
involved in the metabolism, transport, and response to
the drug, as well as receptors that are implicated in
patients’ pain perception and modulation. CYP2D6 plays
a critical role in the formation of active metabolites from
tramadol. The associations between genetic polymorph-
isms of CYP2D6 and therapeutic failure or adverse events
to tramadol have been reported in multiple case reports
and clinical studies. However, the clinical utility of
CYP2D6 testing for tramadol dosing remains to be
established. Genetic variations in the drug transporters
have also been implicated in tramadol efficacy and toxi-
city. Loss-of-function genetic polymorphisms in the liver
uptake transporter OCT1 were recently suggested to
affect the hepatic uptake of M1, the active metabolite of
tramadol. Although the effects were found both in vitro
and in vivo, independent validations of the human find-
ings are required to consider OCT1 polymorphisms in the
treatment guidelines. Most of the existing pharmacoge-
netic studies of tramadol response enrolled a limited
number of patients and reported a limited number of
adverse events. There is a need for larger, well-designed
studies that consider both pharmacokinetic and pharma-
codynamic aspects and investigate possible candidate
378 Pharmacogenetics and Genomics 2014, Vol 24 No 7
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genes to improve the robustness of the reported asso-
ciations and to identify novel genetic markers.
Prospective trials that show improvement in clinical
outcomes will be required to establish the value of
genetic testing in pain therapy.
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